a b s t r a c t C3 glomerulopathy (C3G) defines a group of untreatable ultra-rare renal diseases caused by uncontrolled activation of the alternative complement pathway. Nearly half of patients progress to end stage renal failure within 10 years. Cp40, a second-generation compstatin analog in clinical development, is a 14 amino-acid cyclic peptide that selectively inhibits complement activation in humans and non-human primates by binding to C3 and C3b. We hypothesized that by targeting C3 Cp40 would provide an effective treatment for C3G. By investigating its effects in vitro using multiple assays of complement activity, we show that Cp40 prevents complement-mediated lysis of sheep erythrocytes in sera from C3G patients, prevents complement dysregulation in the presence of patient-derived autoantibodies to the C3 and C5 convertases, and prevents complement dysregulation associated with disease-causing genetic mutations. In aggregate, these data suggest that Cp40 may offer a novel and promising therapeutic option to C3G patients as a disease-specific, targeted therapy. As such, Cp40 could represent a major advance in the treatment of this disease.
Introduction
The term C3 glomerulopathy (C3G) defines a group of ultra-rare renal diseases in which dysregulation of the complement cascade drives the underlying disease process (Pickering et al., 2013) . The annual incidence of biopsy-proven disease is 1-2 per million, with both sexes affected equally (Medjeral-Thomas et al., 2014) . Patients present with proteinuria, hematuria and often some degree of renal failure . Median age at diagnosis is 21 years and within 10 years nearly half of patients progress to end stage renal failure (ESRF). Post-transplantation, disease recurrence with allograft loss is a common occurrence (50-75%) (Servais et al., 2012; Lu et al., 2012) .
While the full spectrum of morphological lesions that presents as C3G remains to be determined, all are characterized by glomerular changes in which there is C3-dominant staining by immunofluorescence (IF). The two major subgroups of C3G, dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), are differentiated by electron microscopy (EM). DDD is characterized by extremely dense osmiophilic deposits that markedly thicken the glomerular basement membrane (GBM), while C3GN is defined by some combination of mesangial, subepithelial, subendothelial and/or less dense, discontinuous intramembranous deposits (Sethi and Fervenza, 2014) .
Caused by dysregulation of the alternative pathway (AP) of complement, the most common acquired drivers of disease are autoantibodies to C3 convertase known as C3 nephritic factors (C3Nefs). Although present in many different disease conditions and reported in normal individuals, most DDD patients (80-85%) and many C3GN patients (∼50%) develop these autoantibodies (Servais et al., 2012; Zhang et al., 2012) , which prolong convertase half-life and promote fluid-phase AP dysregulation (Spitzer et al., 1969; Daha et al., 1976) . Autoantibodies against other proteins like Factor B (FB) and Factor H (FH) are also occasionally found (Strobel et al., 2010; Chen et al., 2011; Goodship et al., 2012) . In both DDD and C3GN, the profile of serological complement biomarkers is consistent with over-activity of the AP and terminal pathway (TP) (Zhang et al., 2014) .
There is no disease-specific treatment for C3G. Current treatment measures are designed to support a patient's general health http://dx.doi.org/10.1016/j.imbio.2015.04.001 0171-2985/© 2015 Elsevier GmbH. All rights reserved. and extrapolating from other glomerular diseases, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are considered as an aid to urine protein management (and also for blood pressure control). Limited C3G-specific data on ACEIs and ARBs suggest that the use of these agents is associated with better renal survival (P < 0.0001) (Servais et al., 2012) . Recently, eculizumab, an anti-C5 humanized antibody that prevents terminal complement pathway activity, has been demonstrated to mitigate C3G in some patients (Vivarelli et al., 2012; McCaughan et al., 2012; Daina et al., 2012; Bomback et al., 2012) . However, persistently unchecked C3 convertase activity can lead to disease progression in spite of effective eculizumab-based suppression of the TP (Gurkan et al., 2013) . These findings suggest that more proximal blockade of complement may be therapeutically advantageous. C3 represents an excellent target for intervention, and as such, the compstatin family of peptidic C3 inhibitors is particularly appealing as a possible therapy in C3G (Mastellos et al., 2015) . In this paper, we report the results of in vitro studies using Cp40, a second-generation compstatin analog (Qu et al., 2013 ) that has entered clinical development (AMY-101; Amyndas Pharmaceuticals), as a complement inhibitor in patients with DDD and C3GN.
Materials and methods

Patient and control samples
Thirty-four patients with C3G (17 DDD and 17 C3GN) were enrolled in this study under IRB-approved guidelines. The diagnosis of either DDD or C3GN was made by renal biopsy as described previously (Zhang et al., 2014) . Whole blood was used as a source of genomic DNA, serum and plasma. Pooled normal serum (PNS, complement preserved) was purchased from Innovative Research, Inc. (Novi, MI).
Reagents
Gelatin veronal buffer (GVB)-EDTA (5 mM Barbital, 145 mM NaCl, 10 mM EGTA and 0.1% Gelatin, pH 7.2), GVB-EGTAMg 2+ (5 mM Barbital, 145 mM NaCl, 0.5 mM MgCl 2 , 10 mM EGTA and 0.1% Gelatin, pH 7.2) and DGVB + + buffer (5 mM Barbital, 140 mM Glucose, 71 mM NaCl, 0.5 mM MgCl 2 , 0.15 mM CaCl 2 and 0.1% Gelatin, pH 7.4) were purchased from Boston Bioproducts, Inc. (Worcester, MA). GVB containing Ca N, N , N , N , acid, 5 mM Barbital, 140 mM Glucose, 5 mM TTHA, 71 mM NaCl, 0.3 mM CaC l2 and 0.1% Gelatin, pH 7.4) was prepared as previously described (Nagaki et al., 1974) . Human complement proteins C2, FB and FD and human factor H-depleted (FH-dpl) serum were purchased from Complement Technology, Inc. (Tyler, TX). Non-sensitized sheep erythrocytes (E) and antibody-sensitized sheep erythrocytes (EA, both in Alsever's solution) were purchased from Colorado Serum Co. (Denver, CO) and Complement Technology Inc. (Tyler, TX), respectively. Rat serum was obtained from Pel-Freez Biologicals, Inc. (Rogers, AR). Compstatin analog Cp40 (D-Tyr-Ile-[Cys-Val1MeTrp-Gln-Asp-Trp-Sar-Ala-His-Arg-Cys]-meIle) was prepared by solid phase peptide synthesis and purified as acetate salt using reversed-phase HPLC as described previously (Qu et al., 2013) .
IgG purification
Patient IgG was purified using the Melon Gel IgG Purification Kit (Thermo Scientific, Rockford, IL) and adjusted to 1 mg/ml.
C3Nef assay
All C3Nef assays were performed as described previously . Briefly, C3b was deposited on non-sensitized sheep erythrocytes by FH-dpl/FB partial inactivated serum (FH-dpl serum was treated 50 • C for 5 min). After washes with GVB-EGTA-Mg 2+ buffer, C3 convertase (C3bBb) was constructed by adding purified FB and FD. C3 convertase-bearing cells were incubated with patient-purified IgG. After allowing convertase to decay at 30 • C for 0 and 20 min, any remaining C3 convertase was developed by adding rat serum in GVB-EDTA buffer (1:9 dilution) as a source of C3-C9. Cp40 (5 M) was introduced at different stages of this assay as indicated in Fig. 3a .
C4Nef assay
The C4Nef assay was performed as described previously, with modifications (Ohi and Yasugi, 1994) . Briefly, C1C4b was deposited on EA using PNS in GVB-Ca 2+ -TTHA buffer. After washes, the classical pathway C3 convertase (C4b2a) was made by adding purified C2. C4b2a-bearing cells were incubated with patient-purified IgG. After allowing this convertase to decay at 30 • C for either 0 or 20 min, any remaining C4b2a was developed by adding human FH-dpl serum in GVB-EDTA buffer (1:5 dilution) as a source of C3-C9. Cp40 (5 M) was introduced at different stages of this assay as indicated in Fig. 4a .
Alternative pathway activity by hemolytic assay
The ability of Cp40 to inhibit the AP on cell surfaces was assessed in a hemolytic assay using non-sensitized sheep erythrocytes in GVB-EGTA buffer or in GVB-EDTA buffer as a control for spontaneous lysis. Serum (20 l) with or without Cp40 was mixed with 5 × 10 8 cells to a total volume of 100 l and incubated at 37 • C for 30 min. The reaction was stopped by adding 150 l of ice-cold GVB-EDTA buffer. Non-lysed cells were removed by centrifugation at 1000 × g for 10 min. Optical density (OD) of the supernatant was recorded at 414 nm, calculating percentage lysis as: [OD sample − OD blank ]/[OD (total lysis) − OD blank ]. Total lysis was obtained by using an equivalent volume of water.
Gel electrophoresis
Patient and PNS were mixed at 1:1 under GVB-EGTA buffer (AP activation possible) or GVB-EDTA buffer (AP activation not possible) and incubated at 37 • C for 45 min. C3 degradation products were resolved by electrophoresis on pre-casted agarose Titan gels (Helena Laboratories, Beaumont, TX) and immune-precipitated using a polyclonal anti-human C3 antibody (MP Biomedical Inc., Pittsburgh, PA). Gels were stained with acid blue and quantitated using AlphaEaseFC software (Cell Biosciences Inc., Santa Clara, CA). Cp40 (at a final concentration of 10 M) was introduced with the serum.
Results
Cp40 prevents abnormal hemolysis in C3GN and DDD
Sheep erythrocytes present a non-activating surface to human complement -when normal human serum is mixed with sheep erythrocytes, lysis does not occur (20% by volume in Mg 2+ -EGTA buffer to ensure that AP activation is possible). Since exogenous C3 is not supplemented in this assay and C3G patients often have very low C3, most C3G patients are negative for this assay. However, lysis is seen in approximately 12% of C3G patients with moderately reduced C3. This finding implies the presence of serum factors or genetic mutations that impede the interaction of factor H with C3 convertase. When added to this assay, Cp40 suppressed lysis (final concentrations tested, 5 M and 10 M) in the presence of autoantibodies and genetic mutations (Fig. 1a and b) .
Cp40 prevents abnormal C3 conversion
Incubation of PNS with C3G patient sera provides an exogenous source of C3 (C3G patients can have exceedingly low levels of serum C3). In the presence of uncontrolled convertase activity (under Mg 2+ -EGTA conditions (G) but not under EDTA conditions (D)), the result is the generation of C3 degradation products, which can be resolved by gel electrophoresis. The addition of Cp40 (final concentration 10 M) to this assay prevented lysis (n = 9; 7 DDD, 2 C3GN) ( Fig. 2A and B ).
Cp40 and convertase formation
Compstatin analogs, including Cp40, bind to human but not rodent C3 (Mastellos et al., 2015) , a property that allowed us to study interaction between Cp40 and convertase formation. We built C3 convertase on C3b-bearing cells (E) by providing FB and FD. Cell lysis occurred upon addition of C3-9 (rat serum-EDTA). We then tested whether Cp40 could prevent binding/activation of substrate C3 by introducing the inhibitor after the formation of C3bBb. Lysis was prevented ( Fig. 3; diamond 2) .
Formation of C5 convertases requires the addition of C3b to existing C3 convertases (C3bBb of the AP or C4b2a of the CP). To test whether Cp40 prevents this step from occurring, we used the CP C3 convertase, C4b2a, since this convertase does not have a target for Cp40 (there is no C3b). After building C4b2a on erythrocytes, we added PNS diluted in GVB-EDTA buffer as a source of C3-C9. Cell lysis occurred after 1hr incubation at 37 • C. When Cp40 (5 M) was introduced after C2 ( Fig. 4 ; diamond 1 blue), no lysis was observed. Lysis did occur if we developed cells with rat serum-EDTA (data not shown) or added human C3 together with C2. These findings mean that Cp40 prevents C5 convertase formation but has no effect on the activity of existing C5 convertase ( Fig. 4b ; diamond 1 orange).
Cp40 and C3Nef
Most C3G patients circulate C3 convertase-stabilizing autoantibodies called C3Nefs. To investigate whether Cp40 restores complement regulation in the presence of these autoantibodies, we added Cp40 at different time points in the hemolytic assay (either with patient-purified IgG or with rat serum-EDTA). Addition of Cp40 (5 M) prevented hemolysis, implying that Cp40 prevents the cleavage activity of C3Nef-stabilized C3 convertase [n = 13 (5 DDD and 8 C3GN)] (Fig. 3b ).
Cp40 and C4Nef
To investigate whether Cp40 prevents C4Nef-mediated complement dysregulation, we tested the classical pathway C3 convertase, C4b2a, stabilized for at least 20 min using C4Nef derived from 3 patients (1 DDD and 2 C3GN). In this assay, C4b2a-bound cells were developed using PNS-EDTA. The effect of Cp40 on C4Nef-stabilized C4b2a was evaluated by adding Cp40 either with patient-purified IgG or with PNS serum-EDTA. At both time points, Cp40 (5 M) prevented hemolysis. When the assay was developed using rat serum-EDTA as a source of C3-C9, hemolysis occurred, consistent with the inability of Cp40 to bind to rodent C3 (data not shown). These data imply that Cp40 corrects C4Nef-mediated complement dysregulation.
Discussion
Patients with C3G have hematuria, proteinuria and low serum C3 at clinical presentation; most also have hypertension and edema. Although a renal biopsy is required for an unequivocal diagnosis (Pickering et al., 2013) , once a diagnosis is confirmed, treatment options to prevent progression to ESRF are limited. For this reason, as data implicating complement dysregulation in C3G have become more robust, clinicians have turned to available anti-complement drugs as potential therapy. There are now a few reports describing the efficacy of eculizumab in C3G (Vivarelli et al., 2012; McCaughan et al., 2012; Daina et al., 2012; Bomback et al., 2012; Le Quintrec et al., 2015) .
Eculizumab binds C5 and prevents its cleavage by C5 convertase. The direct result is two-fold: the potent anaphylatoxin, C5a, is not generated and the production of C5b-9 is prevented. Thus, eculizumab should be an effective in the subset of C3G patients with dysregulation of C5 convertase (Zhang et al., 2014) . In patients with dysregulation of both C3 and C5 convertases, or exclusively at the level of C3 convertase, C5 blockade does not prevent disease progression (Bomback et al., 2012; Gurkan et al., 2013; Berthe-Aucejo et al., 2014) . These observations are consistent with murine models of C3G (Cfh −/− C5 −/− ) in which disease is ameliorated but not completely corrected (Pickering et al., 2006) . These data also confirm the need for more proximal inhibition of complement in C3G patients.
Several therapies that target C3 or C3 convertase are under development. These drugs can be classified broadly as antibodybased therapeutics, which aim to control complement by blocking specific components of C3 convertase to prevent its formation and/or function (e.g., anti-C3b monoclonal antibody (PaixaoCavalcante et al., 2014) ; anti-FB antibody (Subias et al., 2014) ; anti-properdin antibody (Kimura et al., 2010) ), and regulationbased strategies, which aim to control complement by augmenting control of the C3 convertase (e.g., soluble CR1 ; mini-FH (directly links the regulatory and surface targeting domains of FH) (Schmidt et al., 2013) ; TT30 (combines the regulatory domain of FH with the iC3b/C3d-binding domain of CR2) (Risitano et al., 2012) ). Clinical experience with these new drugs in C3G patients is nearly non-existent .
Unique amongst C3/C3 convertase-targeting therapies is Cp40, a small peptide that binds to C3. Since physiological concentrations of plasma C3 are very high (∼1.3 g/L) and its turnover is rapid, sustained effective inhibition of C3 convertase may require comparatively large doses of any therapeutic to achieve sustained target saturation. In this regard, the second-generation compstatin analog Cp40 is particularly attractive. Cp40 is the most recent compstatin analog to be developed. As compared to the original compstatin, it shows significant improvement in binding affinity to human C3 (6000-fold), enhanced inhibitory potency, and a largely extended in vivo half-life (∼12 h after single intravenous injection) (Qu et al., 2013; Mastellos et al., 2015) .
To gain insight into the possibility of AP regulation with Cp40 in C3G, we performed a battery of tests using patient sera and plasma samples. Since not all patients are positive for all tests, we selected 34 samples (17 DDD and 17 C3GN) from our registry. We typically use a direct hemolytic assay with non-sensitized sheep erythrocytes as a screening test to determine whether ongoing AP dysregulation is present. Although only a small percentage of patients are positive on this assay (∼12%) Cp40 prevented AP dysregulation independent of the underlying disease trigger in all positive patients (Fig. 1) .
IFE is a fluid phase assay used most frequently as an indirect test for C3Nefs, autoantibodies that extend the half-life of C3 convertase several fold. Cp40 arrested abnormal C3 turnover in all C3G we tested (Fig. 2) . Finally, the direct effect of Cp40 on complement activation by purified nephritic factors (C3Nefs and C4Nefs from 16 patients) strongly support our therapeutic concept: comprehensive C3 inhibition can be an effective treatment strategy for C3G regardless of the presence of C3Nefs or C4Nefs (Figs. 3 and 4) . As down-stream complement control occurs in the presence of Cp40, the formation of C5 convertase and the generation of C5a, soluble C5b-9, and lytic membrane attack complex are also prevented.
All complement-inhibition strategies increase susceptibility to infection, which is a major clinical concern. However, pretreatment vaccination can substantially reduce the risk of infection. Long-term eculizumab use (over 2 years) reports only 2 patients of 195 who developed meningococcal infections caused by nonvaccinated strains; these patients were treated with antibiotics (Hillmen et al., 2013) . Although long-term inhibition at the level of C3 has not been evaluated clinically to date, inherited deficiencies of C3 are reported and suggest that infection risk for infection is increased only to a limited set of pathogens in younger persons (Reis et al., 2006) . Thus Cp40 therapy may require prophylactic antibiotics and/or vaccination against encapsulated bacteria, including meningococci, pneumococci and haemophilus influenza.
To date, Cp40 has been evaluated in several disease models, including paroxysmal nocturnal hemoglobinuria, hemodialysisinduced inflammation and periodontal disease (Maekawa et al., 2014; Reis et al., 2014; Risitano et al., 2014) . To this list we now add C3G. If Cp40 is able to offer to C3G patients a disease-specific, targeted therapy, this drug will represent a major advancement for these patients.
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